Business Wire

LS Mtron Participates in ‘Agritechnica 2019’ Accelerating Its Advance into Europe

28.11.2019 11:00:00 EET | Business Wire | Press release

Share

LS Mtron (CEO Andy Kim) announced on November 28 that it had participated in ‘Agritechnica 2019’ held in Hanover, Germany from November 10 through the 16.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191128005173/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

LS Mtron of Korea, specializing in industrial machines and state-of-the-art components, participated in ‘Agritechnica 2019’. The company has participated in the exhibition since 2015. This year, LS Mtron had a booth covering 205 square meters to showcase its products. Under banners reading “Change Your Standard,” LS Mtron exhibited products that stressed both ‘reliability’ and ‘rationality’. In particular, tractors featuring innovative futuristic design and technology were favorably received by visitors. (Photo: Business Wire)

Under banners reading “Change Your Standard,” LS Mtron exhibited products that stressed both ‘reliability’ and ‘rationality’. In particular, tractors featuring innovative futuristic design and technology were favorably received by visitors.

In 2003, LS Mtron was spun off from LG Group as an affiliate specializing in industrial machines and state-of-the-art components. Last year, sales amounted to KRW1.1 trillion. LS Mtron, with its annual production capacity of 50,000 units, has the largest share of the Korean tractor market. The company also exports to more than 40 countries, including the US, Brazil, China, etc., with its global production and sales bases playing key roles.

Significantly, last year, LS Mtron received the ‘Tractor of the Year’ award at the North American Equipment Dealers Association’s ‘Dealer’s Choice’ awards for the 5th consecutive years. In addition, LS Mtron is ‘Korea’s No.1 Tractor’ maker that is using ICT technology to lead the agricultural machinery industry in remote diagnostic services and cutting-edge autonomous tractor technologies.

This year, LS Mtron had a booth covering 205m2 to showcase its products in ‘Agritechnica 2019’. The slogan for the event ‘Change Your Standard’ was chosen to present maximum reliability and rationality to European customers and change the anchor purchases with excellent product fundamentals, innovative design, compelling performance, full support for dealers, and supplying parts at the right place at the right time.

LS Mtron introduced 7 models ranging from an 18ps Sub-compact model to the 150ps Row-crop model which can appeal to European customers. The futuristic ‘MTX (tentative)’ concept tractor is thought to have taken the streamlined design of existing products a step further. The company has applied a strong and sharp design language with headlamps resembling the fierce eyes of an angry bull that clearly say that LS Mtron products can provide ‘powerful and faithful work performance’. The Utility tractor, 100ps ‘XP’ model, scheduled to be launched in Europe in 2020 especially drew the attention of visitors. The XP tractor, based on its powerful engine and cutting-edge technology, makes it possible to move forward and backward easily without the manual operation of clutches when using the improved power shuttle. And as it comes standard with LED headlamps instead of halogen, its workability at night has also been improved.

In particular, during the exhibition, LS Mtron entered into an MOU for the development of e-Tractors with Austria’s AVL, the world’s best powertrain development and testing company. The two companies are planning to capitalize on this MOU to develop Sub-Compact e-Tractors and produce highly-efficient and eco-friendly tractors. LS Mtron will proactively present the direction of its eco-friendly models of the future to the European market and introduce a broader lineup of various models to make inroads into the lawn & garden and landscaping markets.

LS Mtron is planning to leverage its participation in the exhibition to develop new models and technologies customized for Europe. The company has established a roadmap for the launch of new models starting with the new premium MT2 and utility tractors in 2020 and plans to proactively respond to environmental protection and regulatory changes by successively launching new models based on the Stage V engine in 2021. In January 2020, LS Mtron will become the first Korean company in the industry to restrict the use of hazardous materials containing phthalates, thereby promoting the safety of customers and eco-friendliness.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LS Mtron
Jae Woo Lee
+82-31-8045-9667
unforgiven81@lsmtron.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye